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in Ischemic Retinopathy
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Abstract
Aims: Ischemic retinal diseases such as retinopathy of prematurity are major causes of blindness due to damage
to the retinal microvasculature. Despite this clinical situation, retinopathy of prematurity is mechanistically
poorly understood. Therefore, effective preventative therapies are not available. However, hypoxic-induced
increases in reactive oxygen species (ROS) have been suggested to be involved with NADPH oxidases (NOX),
the only known dedicated enzymatic source of ROS. Our major aim was to determine the contribution of NOX
isoforms (1, 2, and 4) to a rodent model of retinopathy of prematurity. Results: Using a genetic approach, we
determined that only mice with a deletion of NOX1, but not NOX2 or NOX4, were protected from retinal
neovascularization and vaso-obliteration, adhesion of leukocytes, microglial accumulation, and the increased
generation of proangiogenic and proinflammatory factors and ROS. We complemented these studies by showing
that the specific NOX inhibitor, GKT137831, reduced vasculopathy and ROS levels in retina. The source of NOX
isoforms was evaluated in retinal vascular cells and neuro-glial elements. Microglia, the immune cells of the
retina, expressed NOX1, 2, and 4 and responded to hypoxia with increased ROS formation, which was reduced
by GKT137831. Innovation: Our studies are the first to identify the NOX1 isoform as having an important role in
the pathogenesis of retinopathy of prematurity. Conclusions: Our findings suggest that strategies targeting
NOX1 have the potential to be effective treatments for a range of ischemic retinopathies. Antioxid. Redox Signal.
20, 2726–2740.
Introduction
In ischemic retinopathies such as retinopathy of prema-turity and diabetic retinopathy, tissue hypoxia is a pre-
dominant causative factor for the capillary degeneration and
pathological neovascularization that characterize these dis-
eases (45, 51). Retinopathy of prematurity is themajor cause of
vision loss and blindness in the neonate, a situation that is
escalating in prevalence throughout the world (20, 60). Re-
tinopathy of prematurity develops in some preterm infants
following exposure to monitored hyperoxia, which disrupts
physiological vascularization resulting in areas of vaso-
obliteration (51). After subsequent maturation of the infant
and return to room air, the nonvascularized retina becomes
increasingly hypoxic. These changes in the retinal microen-
vironment stimulate the production of angiogenic factors,
such as vascular endothelial growth factor (VEGF) and
erythropoietin, resulting in pathological neovascularization
(8, 45, 51). The vasculopathy that occurs in retinopathy of
prematurity and diabetic retinopathy involves not only
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vascular cells but also nonvascular cells (16). Indeed, inflam-
matory cells and the immune cells of the retina, microglia,
play a critical role in the development and repair of the vas-
culature in retinopathy of prematurity (43, 50).
The treatment strategies for retinopathy of prematurity
remain unsatisfactory. The main approach is the use of laser
photocoagulation to decrease areas of damaged and hypoxic
retina (31, 45). However, this treatment only provides ben-
efits in the end stage of the condition, and unfortunately,
neither prevents disease progression nor completely pre-
vents vision loss. Therefore, new strategies that target the
underlying mechanisms involved in the development of
retinopathy of prematurity are urgently required (10, 12). A
likely critical pathomechanism is an excessive generation of
reactive oxygen species (ROS). The neonatal retinamaintains
a high rate of oxidative metabolism, which is exacerbated in
retinopathy of prematurity by an inadequate ability to
scavenge ROS due to reduced levels of antioxidants (35).
Clinical studies have evaluated the use of antioxidants, such
as vitamins C and E. However, the results have been in-
consistent (35, 42), which is likely to be due, at least in part,
to these approaches having suboptimal effects in reducing
ROS accumulation.
There is considerable interest in the role of the NADPH
oxidase (NOX) family in a wide range of ischemic and ROS-
mediated vascular pathologies (3, 5, 17, 59). This is due to the
uniqueness of this enzyme family as they are the only en-
zymes with their sole function being the generation of ROS.
Seven isoforms of the NADPH oxidase catalytic unit, NOX
(NOX1–5, DUOX1, DUOX2), have been identified, of which
NOX1, NOX2, and NOX4 are considered to be relevant to
vasculopathy (3, 5, 17, 56, 59). Strategies to reduce NOX ac-
tivity and the generation of ROS, such as naturally occurring
flavonoids, have recently been shown to have benefits in
retinal pathology (7, 25). However, the relative contribution of
individual NOX isoforms to retinal neovascularization is not
known. Identifying the pathologically relevant NOX iso-
form(s) has the potential to provide a new and effective pre-
ventative treatment approach for retinopathy of prematurity.
Furthermore, the advent of more specific pharmacological
approaches to inhibit certain NOX isoforms, such as
GKT137831, represents a new treatment strategy. Indeed, this
compound is an orally active NOX inhibitor with a relative
specificity for NOX1 and NOX4 (4, 19).
To determine the contribution of NOX isoforms to reti-
nopathy of prematurity, we used a robust in vivo model
known as oxygen-induced retinopathy (OIR). We induced
OIR in mice with deletions of the NOX1, NOX2, or NOX4
isoforms and also evaluated the effects of GKT137831 in
mice and rats with OIR. Vascular injury and inflammation
as well as the levels of proangiogenic and proinflammatory
markers and ROS were examined in retina. To determine
the cellular source of NOX in retina, we studied primary
cultures of retinal vascular and neuro-glial elements and
examined the effects of GKT137831 on hypoxic-induced
ROS production in retinal microglia. We have clearly
identified NOX1 as the first molecular treatment target
for vasculopathy and the excessive production of ROS in
retinopathy of prematurity. Our findings therefore have
implications for the treatment of various ischemic
retinopathies.
Results
Body weight gain
As reported previously, the body weight gain of animals
with OIR was reduced compared to room air controls (14).
There was no effect of NOX1 and NOX4 isoform deletion on
body weight gain. However, NOX2 knockout (KO) mice with
OIR had reduced body weight gain compared to NOX2 WT
OIR mice. GKT137831 had no effect on body weight gain
compared to untreated OIR rats (Supplementary Table S1;
Supplementary Data are available online at www.liebertpub
.com/ars).
NOX1 KO mice with OIR exhibit reduced retinal
neovascularization, vaso-obliteration,
and vascular leakage
To determine if NOX1, NOX2, and NOX4 are present in
retina, we qualitatively evaluated gene expression in
C57BL/6 mice. Given that all the three isoforms were ex-
pressed (Fig. 1A), we next determined which NOX isoform
contributes to vasculopathy in OIR. Therefore, we studied
NOX1 KO, NOX2 KO, and NOX4 KO mice. We first deter-
mined that retina from NOX KO mice exhibited a deficiency
in the relevant NOX isoform (Fig. 1A) and KO mice did not
have compensatory changes in NOX isoform expression
(Supplementary Fig. S1A–C). In room air controls, vascu-
larization of the retina was normal. As expected, in all WT
mice with OIR, retinal neovascularization and an avascular
vaso-obliterated central retina were present (Fig. 1B–D). In
NOX1 KOmice with OIR, retinal neovascularization and the
avascular central retina were clearly markedly reduced
compared to NOX1 WT mice with OIR. However, in NOX2
KO mice and NOX4 KO mice with OIR, neovascularization
and the avascular central retina were not reduced compared
to respective WT OIR (Fig. 1B–D). The findings for neo-
vascularization were confirmed in paraffin sections of retina
(Supplementary Fig. S2A, B). Breakdown of the blood–
retinal barrier and subsequent vascular leakage is a major
contributor to vision loss (16, 39). Indeed, retinal vascular
leakage occurred inWTmice with OIR compared to room air
controls (Fig. 1E). In NOX1 KO mice with OIR, retinal vas-
cular leakage was reduced compared to NOX1 WT controls
with OIR. However, in NOX2 KO mice and NOX4 KO mice
with OIR, retinal vascular leakage was not affected com-
pared to respective WT mice with OIR (Fig. 1E).
Innovation
Our study provides novel insight into the role of par-
ticular NADPH oxidase (NOX) isoforms in the develop-
ment of vascular injury, inflammation, and oxidative stress
in ischemic retinopathy. Furthermore, the presence of
NOX isoforms in retinal vascular and nonvascular cells
suggests that particular cell populations drive reactive
oxygen species (ROS)/NOX-mediated damage. We spec-
ulate that the inhibition of pathological NOX isoformsmay
provide a new avenue for the treatment of ischemic re-
tinopathies, such as retinopathy of prematurity, where
preventative mechanism-based therapies are urgently
required.
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NOX1 KO mice with OIR exhibit reduced leukostasis
As inflammation is known to contribute to the develop-
ment of vasculopathy in OIR (23, 29, 61), we evaluated the
extent of leukocyte adherence to the retinal vasculature. In
room air controls, few adherent leukocytes were detected in
retinal blood vessels (Fig. 2A, B). As expected, in WT mice
with OIR, retinal leukostasis was increased compared to room
air controls (Fig. 2A, B). Importantly, in NOX1 KO mice with
OIR, retinal leukostasis was reduced compared to NOX1 WT
micewith OIR to the level seen in room air controls. However,
in NOX2KO andNOX4KOmicewith OIR, retinal leukostasis
was not reduced compared to respective WT OIR mice
(Fig. 2A, B).
NOX1 KO mice with OIR exhibit reduced labeling
for the microglial marker, ionizing binding adaptor
molecule-1
Microglia are resident inflammatory cells of the retina,
which contribute to vascular remodeling in OIR (43) and are
known source of ROS (55). Using the microglial marker,
ionizing binding adaptor molecule-1 (Iba1), we investigated
the degree of immunolabeling in the region of the retina
FIG. 1. In OIR, NOX1 KOmice, but not NOX2 KO and NOX4 KOmice, exhibit reduced retinal vasculopathy. (A)NOX1,
NOX2, and NOX4 mRNAs were detected in C57BL/6 mouse retina but were absent in retinas from their respective KO
strains. S, 100 bp ladder. Mouse NOX1, 168 bp; NOX2, 351 bp; NOX4, 156 bp. (B) Retinal wholemounts were labeled with
fluorescein isothiocyanate-lectin to show vascularization (green). In OIR groups, the same image is psuedocolorized to show
neovascularization (red). In room air control WT and KO mice, neovascularization and an avascular retina were not present.
In WT mice with OIR, neovascular tufts (arrows) were detected in the mid-periphery, and the central retina (asterisk) was
avascular. In NOX1 KO mice with OIR, neovascular tufts were reduced by 82% (C) and the avascular retina was reduced by
97% (D) compared with NOX1 WT mice with OIR. In NOX2 KO and NOX4 KO mice with OIR, neovascular tufts and the
avascular retina were not reduced compared to respective WT OIR mice. Original magnification, · 100. Scale bar, 0.25mm.
***p< 0.005 to NOX1 WT OIR. n = 7–9 mice per group. Three litters per group were evaluated. (E) In WT mice with OIR,
retinal vascular leakage was increased compared to room air controls. Only in NOX1 KO mice with OIR was retinal vascular
leakage reduced compared to respective WT OIR mice. *p < 0.05 to respective room air controls. #p < 0.05 to NOX1 WT OIR.
n = 6–8 mice per group. Values are mean – SEM. NOX, NADPH oxidase; OIR, oxygen-induced retinopathy; KO, knockout.
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FIG. 2. In OIR, retinal leu-
kostasis is reduced in NOX1
KO mice but not in NOX2
KO and NOX4 KO mice.
Leukocytes were identified
with rhodamine-concanava-
lin A. (A) In room air control
WT mice, few adherent leu-
kocytes (arrows) are present.
(A, B) In WT mice with OIR,
leukostasis was increased
compared to room air con-
trols. (A, B) Only in NOX1
KO mice with OIR was leu-
kostasis reduced compared to
respective WT OIR. Original
magnification, · 100. Scale
bar, 35lm. Values are
mean – SEM. **p < 0.01 to re-
spective room air control
groups. ##p< 0.01 to NOX1
WT OIR. n = 5–6 mice per
group.
FIG. 3. In OIR, immunolabeling for the microglial marker, Iba1, is markedly reduced in NOX1 KO mice but not in
NOX2 KO and NOX4 KO mice. (A) In WT mice with OIR, Iba1 immunolabeling was increased compared to room air
controls and often associated with blood vessels (*) at the retinal surface. (A, B) In NOX1 KO mice with OIR, Iba1 im-
munolabeling was markedly reduced compared to NOX1 WT mice with OIR. (A, B) In NOX2 KO mice with OIR, Iba1
immunolabeling was similar to NOX2 WT mice with OIR and associated with pre-retinal vessels protruding into the vitreous
cavity. In NOX4 KO mice with OIR, Iba1 immunolabeling was slightly reduced compared to NOX4 WT mice with OIR,
although still present in pre-retinal blood vessels. Original magnification, · 400. Scale bar, 60lm. Counterstain, hematoxylin.
Values are mean – SEM. *p< 0.02 to respective room air controls. **p < 0.01 to respective room air controls. ##p< 0.01 to NOX1
WT OIR. {p < 0.02 to NOX4 WT OIR. n = 5–6 mice per group. GCL, ganglion cell layer; IPL, inner plexiform layer; Iba1,
ionizing binding adaptor molecule-1.
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associated with pre-retinal neovascularization. As previously
reported (14), the degree of Iba1 immunolabeling was in-
creased in WT mice with OIR compared to room air controls.
Immunolabeling for Iba1 was often associated with blood
vessels (Fig. 3A, B). In NOX1 KO mice with OIR, Iba1 im-
munolabeling did not increase as seen in NOX1WTmice with
OIR (Fig. 3A, B). InNOX2KOmicewithOIR, the extent of Iba1
immunolabeling was similar to NOX2 WT mice with OIR,
with this labeling associated with pre-retinal blood vessels. In
NOX4 KO mice with OIR (Fig. 3A, B), Iba1 immunolabeling
was not elevated to the same extent as NOX4 WT mice with
OIR, although still present in pre-retinal blood vessels.
NOX1 KO mice with OIR exhibit reduced expression
of angiogenic and inflammatory factors
To determine if angiogenic and inflammatory factors, which
are known to be involved in the development of OIR (6, 8, 37,
40), were reduced in the KO mice, we studied the gene ex-
pression of VEGF, erythropoietin, angiopoietin-2, and inter-
cellular adhesionmolecule-1 (ICAM-1) in retina by quantitative
polymerase chain reaction (PCR). As expected, in WT mice
with OIR, retinal mRNA levels of all factors were increased
compared to room air controls (Fig. 4A–D). Consistent with the
decrease in retinal vasculopathy and leukostasis, in NOX1 KO
mice with OIR, retinal mRNA levels of these particular mole-
cules implicated in angiogenesis and inflammation, were re-
duced compared to NOX1 WT mice with OIR (Fig. 4A–D). By
contrast, in NOX2 KO and NOX4 KO mice with OIR, the
mRNA levels of all these factors were unaltered compared to
respective WT mice with OIR (Fig. 4A–D).
NOX1 KO mice with OIR exhibit reduced retinal
VEGF protein
Given VEGF’s predominant role in retinal vasculopathy
and inflammation in OIR (40), we performed VEGF im-
munolabeling. In room air controls, VEGF immunolabeling
was barely detectable and mainly observed on the inner
limitingmembrane and occasionally in ganglion cells (Fig. 5A).
In WT mice with OIR, intense VEGF immunolabeling was
observed in pre-retinal neovascular vessels protruding into the
vitreous cavity, in some intraretinal blood vessels, ganglion
cells, and processes of macroglial Mu¨ller cells. In NOX1 KO
mice with OIR, but not in NOX2 KO and NOX4 KOmice with
OIR, VEGF labeling in all regions was markedly reduced
compared to respective WT mice with OIR (Fig. 5A, B).
NOX1 KO mice with OIR exhibit reduced levels
of ROS in retina
We next evaluated whether the improvements in OIR that
occurred in NOX1 KOmice were accompanied by a reduction
in ROS levels in the retina. As expected in all groups, dihy-
droethidium (DHE) labeling for ROSwas present in regions of
high oxygen consumption, such as the outer nuclear layer
(photoreceptor nuclei) and the inner nuclear layer (mainly
macroglial Mu¨ller cell nuclei) (Fig. 6A). However, in WTmice
with OIR, DHE labeling was also detected in the area of pre-
retinal neovascularization at the retinal surface (inner limiting
membrane and ganglion cell layer) (Fig. 6A). Consistent with
our findings of a reduction in neovascularization inNOX1KO
mice with OIR, retina from these mice exhibited reduced
DHE labeling in the region of pre-retinal neovascularization
FIG. 4. In OIR, quantitative PCR of retina showed that NOX1 KO mice, but not NOX2 KO and NOX4 KO mice,
exhibited reduced mRNA levels of angiogenic and inflammatory factors in retina. In WT mice with OIR, VEGF (A), EPO
(B), angiopoietin-2 (C), and ICAM-1 (D)mRNA levels in retina were increased compared to room air controls. Only in NOX1
KO mice with OIR were the mRNA levels of these factors reduced compared to respective WT OIR and to the level of room
air controls. *p< 0.05 to respective room air controls. *p< 0.05 and **p< 0.01 to respective room air controls. #p< 0.05 and
##p< 0.01 to NOX1 WT OIR. n = 6–10 mice per group. Values are mean– SEM. ICAM-1, intercellular adhesion molecule-1;
VEGF, vascular endothelial growth factor; EPO, erythropoietin; PCR, polymerase chain reaction.
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compared to WT mice with OIR (Fig. 6A, B). However, in
NOX2 KO and NOX4 KO mice with OIR and pronounced
retinal neovascularization, DHE labeling persisted in the re-
gion of neovascularization (Fig. 6A, B). Similar to findings for
DHE labeling, we found that labeling for nitrotyrosine, a
marker of peroxynitrite-induced damage, was localized to
pre-retinal blood vessels in WT mice with OIR and was vir-
tually absent in retina from room air controls (Fig. 7A, B). This
pattern of labeling is consistent with previous reports in the
OIRmodel (53). In NOX1 KOmice with OIR, but not in NOX2
KO and NOX4 KO mice with OIR, nitrotyrosine labeling
was reduced compared to respective WT mice with OIR
(Fig. 7A, B).
GKT137831 inhibited hypoxia-induced ROS
generation by microglia and reduced retinal
vasculopathy in OIR
As it is not clear which retinal cell populations express
particular NOX isoforms, we evaluated NOX expression
profiles in primary retinal cultures. A qualitative rather than
quantitative assessment was required as retina and cultures
were obtained from different species (rats and cows). Studies
were not performed in mouse retinal cells as the small size of
the neonatal mouse retina hinders the acquisition of a suffi-
cient number of cells for culture. In cultures of retinal rat
microglia, ganglion cells and pericytes, NOX1, NOX2, and
NOX4, were expressed, whereas cultured retinal glia ex-
pressed NOX1 and NOX4 and cultured retinal bovine endo-
thelial cells expressed NOX2 and NOX4 (Fig. 8A–C).
Previously, the role of NOX5 has not been evaluated in retina
due to its absence from rats and mice, although it is present in
other mammals, including humans and cows (59). As NOX5
may be relevant to vascular pathology (21), we evaluated its
expression in human retina and in bovine retinal endothelial
cells and bovine retinal pericytes. NOX1, 2, 4, and 5 were
present in human retina (Supplementary Fig. S3A), andNOX5
was present in both bovine retinal endothelial cells and peri-
cytes (Supplementary Fig. S3B).
Based on our findings that retinal microglia express NOX1,
NOX2, and NOX4, and that NOX1 contributes to vasculo-
pathy in OIR, we examined whether microglia are a source of
ROS. We exposed primary cultures of microglia to hypoxia to
mimic the in vivo environment of OIR. Hypoxia for 4 h re-
sulted in increased levels of ROS in cell lysates compared to
normoxia controls. GKT137831 reduced the elevated ROS
levels to that of normoxia controls (Fig. 8D). We next deter-
mined if GKT137831 reduced vasculopathy in OIR. In OIR
rats, and NOX4 WT and KO mice, GKT137831 reduced neo-
vascularization and the avascular retina compared to un-
treated OIR animals (Fig. 8E–J). Both early intervention and
late intervention were equally effective in rats with OIR (Fig.
FIG. 5. In OIR, VEGF immunolabeling is reduced in the inner retina of NOX1 KO mice but not in NOX2 KO and NOX4
KO mice. (A) In room air controls, VEGF immunolabeling was present on the retinal surface (ILM). In WT mice with OIR,
intense VEGF immunolabeling was present in pre-retinal blood vessels (arrows) protruding into the vitreous cavity, some
intraretinal blood vessels in the IPL (asterisk) and Mu¨ller cell processes in the IPL (arrowhead) and INL. (A, B) Only in NOX1
KO mice with OIR was VEGF immunolabeling reduced compared to WT OIR. In NOX2 KO and NOX4 KO mice with OIR,
VEGF immunolabeling was similar to respective WT OIR. Original magnification, · 400. Scale bar, 35 lm. Values are
mean – SEM. *p < 0.05 and **p< 0.01 to respective room air controls. #p < 0.05 to NOX1 WT OIR. n = 5–6 mice per group. ILM,
inner limiting membrane; INL, inner nuclear layer.
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8H–J). GKT137831 also reduced the levels of DHE labeling in
C57BL/6 mice with OIR (Supplementary Fig. S4).
Discussion
The present study provides the first evidence that NOX1,
but not NOX2 or NOX4, has an important role in the devel-
opment of OIR. Using mice with genetic deficiencies in NOX
isoforms, we demonstrated that deletion of NOX1, but not
NOX2 or NOX4, protected against OIR-induced retinal neo-
vascularization, capillary vaso-obliteration, vascular leakage,
and vascular adherence of leukocytes. Furthermore, NOX1
KO mice exhibited in retina reduced the expression of
proangiogenic and proinflammatory factors as well as re-
duced microglial density and ROS levels. The novel dual
NOX1 and NOX4 inhibitor, GKT137831, reduced retinal
vasculopathy in mice and rats with OIR and also in NOX4 KO
mice with OIR. We determined that the vascular and neuro-
glial elements involved in the development of retinal vascular
injury in retinopathy of prematurity are sources of NOX1, 2,
and 4 and that NOX5 is present in human retina. Furthermore,
we identified microglia as a source of hypoxia-induced ROS
generation, which is responsive to GKT137831. This is the first
report to provide direct evidence that NOX1 has a patholog-
ical role in OIR, a finding that has major implications for the
medical treatment of retinopathy of prematurity and other
neovascular ischemic retinopathies.
Vision loss and blindness caused by retinopathy of pre-
maturity is largely a consequence of hypoxia-induced neo-
vascularization and vascular leakage (10). VEGF is arguably
the most important mediator of this pathology (30), with
contributions from other factors, such as erythropoietin (9)
and angiopoietin-2 (37). Our data revealed a predominant role
for NOX1 in promoting the expression of these putative me-
diators of OIR. Few studies have compared the role of NOX
isoforms in angiogenesis in vivo (17, 56), and to our knowl-
edge, none have been performed in retinopathy. Our findings
are in agreement with other studies investigating the role of
NOX isoforms in angiogenesis, although these experiments
were performed in other organs. For example, basic fibroblast
growth factor-stimulated angiogenesis in matrigel plugs was
reduced in NOX1 KOmice but not in NOX2 KO or NOX4 KO
mice (17). A key role for NOX1 in angiogenesis has also been
reported in tumors where NOX1 was suggested to be the
angiogenic switch for VEGF-related vascular growth (5).
These results for NOX1 contrast those studies that showed
angiogenic functions for NOX2 and NOX4. In NOX2 KOmice
with VEGF-loaded sponge implants, angiogenesis was
reduced (54). Angiogenesis was blunted in NOX4 KO mice
with femoral artery ligation (47), whereas in cardiomyocyte-
specific NOX4 overexpressing mice, myocardial capillary
density was increased (62). The reasons for the divergent
angiogenic roles of the NOX isoforms are not clear; however,
it is possible that the influence of particular NOX isoforms on
angiogenesis depends on the tissue environment. In this re-
gard, it can be speculated that the drivers for neovascular-
ization in OIR, namely intense hypoxia and contributions
from inflammatory cells (23, 43), favor NOX1 over other NOX
FIG. 6. In OIR, NOX1 KO mice, but not NOX2 KO and NOX4 KO mice, have reduced ROS in the region of pre-retinal
neovascularization. (A) In all groups, DHE labeling for ROS was present in the outer retina in the ONL and INL. However, in
WT mice with OIR, DHE labeling was also present at the retinal surface on pre-retinal blood vessels protruding into the
vitreous cavity (arrows) and in the GCL. (A, B) In NOX1 KO mice with OIR, DHE labeling was barely detectable at the retinal
surface and GCL. In NOX2 KO and NOX4 KO mice with OIR, DHE labeling was present on pre-retinal blood vessels.
Original magnification, · 200. Scale bar, 70lm. Values are mean – SEM. *p< 0.05 and **p < 0.01 to respective room air controls.
#p< 0.05 to NOX1 WT OIR. n= 5–6 mice per group. ONL, outer nuclear layer; DHE, dihydroethidium; ROS, reactive oxygen
species.
2732 WILKINSON-BERKA ET AL.
isoforms. Of interest are the mechanisms by which hypoxia
influences NOX1 expression and activity. Furthermore, it will
be important to determine howNOX1 expression and activity
influence the production of angiogenic and inflammatory
genes during the development of OIR, and particularly the
contribution of hypoxic-inducible factor-1a, which is upre-
gulated in the acute stage of OIR (34).
The early stage of OIR in mice features hyperoxia-induced
capillary vaso-obliteration resulting in an avascular central
retina. The extent of damage is viewed to predict the severity
of neovascularization in OIR (28). Elevated levels of ROS are
thought to be involved in this capillary degeneration as in-
travitreal administration of liposome-encapsulated superox-
ide dismutase (36) and systemically administered Trolox, a
water-soluble analogue of vitamin E (39), reduce the avascu-
lar area in OIR. Our data extend these findings by highlight-
ing that NOX1, but not NOX2 orNOX4, is likely to be a source
of ROS, which mediates capillary degeneration in OIR.
Leukocytes contribute to OIR by remodeling the retinal
vasculature and/or delivering inflammatory mediators, cy-
tokines and possibly ROS to influence neovascularization (23,
43). In OIR, leukocytes adhere to the retinal vasculature (58).
We demonstrated that a deficiency in NOX1, but not in NOX2
or NOX4, reduces retinal leukostasis in OIR. Furthermore,
there was a reduction in ICAM-1 levels in NOX1 KO mouse
retina consistent with the previously reported major role of
ICAM-1 in retinal leukostasis (32). To our knowledge, little is
known about the contribution of NOX2 and NOX4 to retinal
inflammation in OIR. It has been reported that lipopolysac-
charide-induced as well as diabetes-induced leukostasis and
ICAM-1 expression were reduced in NOX2 KO mice (2). The
reasons for the differences between these findings and our
results may, as previously mentioned, relate to the particular
retinal disease being evaluated. However, it is possible that
given NOX2’s role in inflammation (41, 48), it may influence
inflammatory processes in the early stages of OIR. Never-
theless, strategies to inhibit NOX2 in patients are not likely to
be appropriate since deficiencies in NOX2 are associated with
compromised phagocytic defense resulting in life-threatening
bacterial and fungal infections (48), a situation that could have
severe consequences for children with retinopathy of prema-
turity who are already prone to infections (29).
Several reports have shown that ROS levels are increased in
the retina after OIR (1, 6, 44, 53) and that untargeted scav-
enging of ROS with agents such as vitamin C derivatives and
the nonspecific NOX inhibitor, apocynin (49), reduce retinal
neovascularization and vaso-obliteration (1, 44). Consistent
with previous studies (1, 53), we found increased ROS levels
in WT mice with OIR in the region of pre-retinal neovascu-
larization. Importantly, we also demonstrated that a defi-
ciency in NOX1, but not in NOX2 and NOX4, reduced this
increase in ROS levels. This finding was substantiated in WT
mice with OIR, where ROS levels in the inner retina were
reduced with GKT137831. A previous study in OIR reported
FIG. 7. In OIR, NOX1 KO mice, but not NOX2 KO and NOX4 KO mice, exhibit reduced nitrotyrosine levels in the inner
retina. Three-micrometer paraffin sections of retinas were counterstained with hematoxylin. (A) In WT mice, immunolabeling
for nitrotyrosine is barely detected and occasionally observed in ganglion cells (arrowheads) in the GCL and in the INL. In WT
OIR mice, intense immunolabeling for nitrotyrosine is observed in these regions and also in pre-retinal blood vessels (arrows)
that protrude into the vitreous cavity. In NOX1 KO mice with OIR, pre-retinal blood vessels are absent and therefore
nitrotyrosine labeling is not apparent, whereas in NOX2 and NOX4 KO mice with OIR, immunolabeling is found on pre-
retinal blood vessels. Original magnification, · 400. Scale bar, 60lm. (B) Values are mean – SEM. **p < 0.01 to respective room
air controls. ##p < 0.01 to NOX1 WT OIR. n = 5 mice per group.
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FIG. 8. GKT137831 (GKT) inhibited hypoxia-induced ROS generation by microglia and reduced retinal vasculopathy in
OIR. NOX1 (A), NOX2 (B), and NOX4 (C) expression was detected in rat RMG, rat RGC, and bovine RP. NOX1 and NOX4,
but not NOX2, were present in rat RG. NOX2 and NOX4, but not NOX1, were present in bovine RE. S, 100 bp ladder. Rat
NOX1, 82 bp; bovine NOX1, 67 bp; rat NOX2, 131 bp; bovine NOX2, 152 bp; rat NOX4, 71 bp; bovine NOX4, 130 bp. (D) In
microglial cell lysates, hypoxia increased ROS levels (DHE) compared to normoxia control. In microglial exposed to hypoxia,
GKT reduced ROS to the level of normoxia control. ****p< 0.0001 to normoxia-untreated (U) control. ####p< 0.0001 to hypoxia-
untreated control. n = 3–4 independent experiments with triplicate samples within each experiment. (E) Retinal wholemounts
from Sprague Dawley rats were labeled with fluorescein isothiocyanate (FITC)-lectin to show vascularization (green). Ori-
ginal magnification, · 100. Scale bar, 0.4mm. Regions from each image are enlarged (boxes) and psuedocolorized to show
neovascularization (red). Original magnification, · 100. Scale bar, 0.04mm. In room air controls, neovascularization and an
avascular retina were not present. In untreated (U) OIR, neovascular tufts (arrows) were detected in the mid-periphery, and
regions of the peripheral retina (marked by the yellow dotted line) were avascular. In rats with OIR, both early and late
treatment with GKT reduced neovascular tufts (F) and the avascular retina (G) compared to untreated OIR. *p< 0.02 to
untreated OIR. **p< 0.01 to untreated OIR. ***p< 0.005 to untreated OIR. n = 6–7 rats per group. (H) Retinal wholemounts
from NOX4WT and KO mice were labeled with FITC-lectin to show vascularization (green). Images were psuedocolorized to
show neovascularization (red). Original magnification, · 100. Scale bar, 0.4mm. In NOX4 WT room air controls, neo-
vascularization and an avascular retina were not present. In NOX4 WT OIR mice that were untreated (U), neovascular tufts
(arrows) were detected in the mid-periphery, and the central retina was avascular (asterisk). In NOX4 WT and KO mice with
OIR, early treatment with GKT reduced neovascular tufts (I) and the avascular retina ( J) compared to untreated OIR.
***p< 0.001 to untreated OIR. n = 8–11 mice per group. Values are mean– SEM. RMG, retinal microglial; RGC, retinal ganglion
cells; RP, retinal pericytes; RG, retinal glia; RE, retinal endothelial cells.
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that ROS levels were reduced when retinal sections were in-
cubatedwithNOX2-tat (a peptide that inhibits NOX assembly
by binding to p47phox and blocking its interaction with
NOX2) (1). However, despite these reported results, we did
not find a reduction in retinal vasculopathy in NOX2 KOmice
with OIR, suggesting that any ROS generated from NOX2 is
likely to have little impact on retinal neovascularization. In-
deed, it remains controversial as to whether NOX2-tat is
specific for NOX2 (59), and thus, its effects may also be me-
diated by inhibition of NOX1.
To determine whether the inhibition of NOX isoforms is a
potential treatment of retinopathy of prematurity, we chose a
complementary pharmacological approach by evaluating the
NOX inhibitor, GKT137831, which inhibits both NOX1 and
NOX4. Studies were performed in NOX4 KO mice with OIR
and also in rats with OIR as the retinopathy, which develops
in rats, more closely mimics that of children with retinopathy
of prematurity (22). GKT137831 had a similar effect to NOX1
deletion in suppressing retinal neovascularization and re-
ducing the extent of loss of retinal avascularity in OIR. These
findings demonstrate the potential of specific NOX isoform
inhibition as a treatment of retinopathy of prematurity in
children.
Neovascularization inOIR is largely driven by the hypoxia-
induced upregulation of VEGF and other angiogenic factors
produced in neurons and glia (52). Therefore, the next logical
step would be to determine the cellular location of NOX iso-
forms in retina. However, this is difficult due to the paucity of
reliable and specific NOX antibodies. Furthermore, antibody
approaches are unlikely to provide information about the
activities of individual NOX isoforms. We therefore per-
formed a qualitative assessment of NOX isoform mRNA
levels in primary cultures of retinal cells involved in neo-
vascularization. Under basal conditions, only microglia,
ganglion cells, and pericytes expressed NOX1, NOX2, and
NOX4. Given that microglia contribute to OIR (43) and are
important producer of ROS and cytokines (50, 55), further
evaluation of this particular cell type was performed. In OIR,
immunolabeling for retinal microglia in the inner retina was
reduced in NOX1 KO mice but remained elevated in NOX2
KO andNOX4KOmice, although there was a small reduction
in NOX4 KO mice. However, the presence of microglia in the
neovascular tufts of retina fromNOX4KOmicewith OIRmay
indicate why retinal neovascularization was not reduced in
these animals. We complemented these in vivo studies by
demonstrating that hypoxia induces the increased production
of ROS in cultured microglia. The ability of GKT137831 to
suppress this increase in ROS confirms the role of NOX in
excess ROS formation in microglia. However, these findings
do not preclude a role for retinal cells other thanmicroglia as a
source of ROS derived from NOXs that contribute to retinal
neovascularization in OIR. For instance, a recent study has
shown that retinal ganglion cells exhibit a preferential in-
crease in NOX1 mRNA rather than NOX2 and NOX4 mRNA
after ischemia (15).
In summary, retinopathy of prematurity is the major ocular
condition causing blindness of the neonate, and its prevalence
has escalated due to the increased survival of younger and
smaller babies. Currently, there are no effective strategies
that prevent or attenuate the vasculopathy of this vision-
threatening disorder. Although anti-VEGF therapies have
been suggested as a treatment option, there are concerns
about detrimental effects of such a treatment approach on
retinal and organ development (13). Our data provide the
first evidence that NOX1 influences retinal vasculopathy in
OIR by the increased production of ROS and subsequent
generation of angiogenic and inflammatory factors (Fig. 9).
NOX1 inhibition has the potential to become an effective
FIG. 9. Schematic diagram showing the
possible involvement of NOX1 in vascular
pathology in the retina. Ischemic re-
tinopathies may lead to the increased gen-
eration of ROS derived from NOX1 from
vascular and neuro-glial cells. This results in
the production of angiogenic and inflam-
matory factors, such as VEGF, EPO, angio-
poietin-2, and ICAM-1. These factors
promote neovascularization, capillary de-
generation, and vascular leakage as well as
inflammation to result in retinal vasculo-
pathy and compromised vision.
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mechanism-based treatment strategy by alleviating the in-
creases in pathologically relevant ROS. Certainly, further
studies evaluating the effects of NOX1 inhibition and
GKT137831 on other aspects of retinal pathology including
neuronal and glial dysfunction are necessary before these
findings can be translated to patients. Furthermore, the ocular
safety profiles of NOX isoform inhibitors such as GKT137831
in patients with retinopathy will need to be established.
Finally, a role for NOX5 in ischemic retinopathy cannot be
entirely excluded given that it is expressed in human retina
and bovine retinal vascular cells, but unfortunately at present
cannot be studied in relevant rodent models. Overall, our
findings are not only relevant for retinopathy of prematurity
but also for other retinopathies and organ pathologies that
feature neovascularization associated with amplified ROS.
Materials and Methods
Animals
All procedures were approved by the Alfred Medical Re-
search and Education Precinct (AMREP) animal ethics com-
mittee and performed according to the National Health and
Medical Research Council (NHMRC) of Australia’s Guide-
lines for the Care of Animals in Scientific Research. In rodents,
OIR develops over two phases comprising vaso-obliteration
(Phase I) and neovascularization (Phase II) (40). Inmice, Phase
I was induced using a previously published protocol with a
minor modification (57). Mice were exposed between post-
natal day (P)7 and P11 to 75% O2 cycled with 20% O2 for 3 h/
day. In rats, Phase I was induced by exposure between P0 and
P11 to 80% O2 cycled with 20% O2 for 3 h/day (14, 33, 58).
Phase II of OIR occurred when mice and rats were placed in
room air from P12 to P18. Controls were in room air for the
entire study (P0–P18). NOX1 KO, NOX2 KO ( Jackson La-
boratories, Bar Harbour, ME), and NOX4 KO (26) mice were
bred on a C57BL/6 background.WT for NOX1KO andNOX4
KO were littermates and for NOX2 KO were C57BL/6 mice.
NOX1 KO mice were a gift from Professor Karl-Heinze
Krause, Geneva, Switzerland (18). Sprague Dawley rats were
purchased from the Australia Research Centre (Perth, Wes-
ternAustralia). Ratswere treatedwithGKT137831 at a dose of
60mg/kg/day between P0 to P18 (early intervention) and
P12 to P18 (late intervention). GKT137831 was dissolved in
dimethyl sulfoxide and administered by subcutaneous injec-
tion (100ll). Controls received dimethyl sulfoxide by subcu-
taneous injection (100 ll). A separate set of NOX4 WT and
NOX4 KO mice with OIR mice were treated with GKT137831
(60mg/kg/day) from P7 to P18 by subcutaneous injection
(100 ll). GKT137831was provided byGenkyotex SA (Geneva,
Switzerland). Mice and rats were killed at P18 with sodium
pentobarbitone (170mg/ml; Virbac, Peakhurst, New South
Wales, Australia).
NOX inhibition
GKT137831, a member of the pyrazolopyridine dione
family is an efficient inhibitor of both NOX1 and NOX4 iso-
forms (Ki in the range of 100–150 nM in cell-free assays of ROS
production using membranes prepared from cells heter-
ologously overexpressing specific NOX enzyme isoforms) (4).
GKT137831 is also a weak inhibitor of the NOX2 isoform in
cell-free assays but does not significantly inhibit neutrophil
oxidative burst at concentrations up to 100lM and does not
inhibit innate microbial bacterial killing in vitro or in vivo
(when used at a concentration of up to 20lM or administered
at 100mg/kg orally, respectively). Furthermore, GKT137831
has no scavenging or antioxidant activity when tested at
10 lM and has an excellent specificity for NOX1 and NOX4
enzymes as shown in an extensive in vitro off-target phar-
macological profiling on 170 different proteins, including ROS
producing and redox-sensitive enzymes (24, 27).
Retinal neovascularization and vaso-obliteration
in retinal wholemounts
Retinal wholemounts were prepared as described previ-
ously (14, 57). More information can be found in Supple-
mentary Data. Seven to nine mice per group were evaluated
from three litters of animals, and six to seven rats per group
were examined. Neovascularization (neovascular tufts) was
defined as clumps of blood vessels that were positively la-
beled for BS-I lectin. Neovascular tufts over the whole retina
were psuedocolorized in red, and Image J software (v3.1;
National Institutes of Health, Bethesda,WA)was used to set a
threshold for red fluorescent labeling, whichwas then applied
to all sections. Neovascular tufts were quantitated over the
whole retina and expressed as a % of neovascular tufts per
retina. The extent of vaso-obliteration (avascular area) in the
central retina (for mice) and mid-peripheral retina (for rats)
was quantitated using the freehand line tool in Image J. The
avascular area was expressed as a percentage of the total
retinal area. Retinal neovascularization was confirmed in 3-
lmparaffin sections from a separate set of NOX1, NOX2, and
NOX4 WT and KO mice, as previously described (14, 57).
Retinal vascular leakage and leukostasis
Elevated levels of albumin in retina are an indicator of
vascular leakage and blood–retinal barrier breakdown (38).
Albumin levels in freshly frozen single retina were measured
according to the manufacturer’s instructions using a com-
mercially available Mouse Albumin Enzyme-linked immuno
sorbent assay quantification set (Bethyl Laboratories, Mon-
tgomery, TX). Albumin values were normalized to dry retinal
weight. Six to eight mice per group were evaluated. To mea-
sure the extent of adherence of leukocytes to the retinal vas-
culature, leukostasis was quantitated as described previously
(57). More information is found in Supplementary Data.
Immunohistochemistry for microglia and VEGF
Immunohistochemistry for the microglial marker, Iba1,
and for VEGF was performed as described previously (14).
Four 3-lm paraffin sections at least 60lm apart were ran-
domly selected from each eye, dewaxed in histolene, and
hydrated in graded ethanols. Antigen retrieval was achieved
by microwaving in 0.1 M citrate buffer for 10min. After
washing with 0.1M phosphate-buffered saline (PBS), pH 7.4,
sections were incubated with 1% normal goat serum in PBS
for 1 h for Iba1 labeling or 10% donkey serum in PBS for 1 h
for VEGF labeling. The sections were then incubated over-
night at 4C with either an anti-Iba1 antibody (1:1000; Wako,
Tokyo, Japan) or a goat anti mouse VEGF164 antibody
(R&D systems, Minneapolis, MN). The sections were washed
three times with PBS and incubated for 30min with either a
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biotin-conjugated goat anti-rabbit IgG (1:200; DakoCytoma-
tion, Glostrup, Denmark) for Iba1 labeling or a biotinylated
donkey anti-goat IgG antibody (1:500; Jackson Immuno-
research, West Grove, PA) for VEGF labeling. After washing
with PBS, the sections were then incubated with the Vectas-
tain ABC standard kit (Vector Laboratories, Burlingame, CA)
for 30–45min and liquid DAB+ substrate chromagen system
(Dakocytomation) for 15 s. The sections were then counter-
stained with Harris’ Haematoxylin for 7min, rinsed in tap
water, dehydrated through graded ethanols, cleared in his-
tolene, and coverslipped with DPX (VWR International Ltd.,
Poole, England). A negative control without the primary an-
tibody and an isotype IgG antibody control were included to
detect nonspecific labeling. In each section, four nonoverlap-
ping fields at · 400 magnification were captured using a Spot
digital camera (SciTech, Preston, Victoria, Australia). Image J
software was used to set a threshold for brown Iba1 im-
munolabeling and brown VEGF immunolabeling, which was
then applied to all captured fields. Immunolabeling was
quantitated using the threshold tool in the inner retina, which
included pre-retinal blood vessels attached to the retinal
surface and protruding into the vitreous cavity. The inner
retina comprised the inner limiting membrane, ganglion cell
layer, and inner plexiform layer. Results are expressed as Iba1
or VEGF immunolabeling per field of inner retina. Five to six
mice per group were evaluated.
Real-time PCR and qualitative assessment of NOX
isoform expression
In mice, this was performed for NOX1, NOX2, NOX4,
VEGF, erythropoietin, angiopoietin-2, and ICAM-1, as de-
scribed previously (14, 57). More information is found in
Supplementary Data. Total RNA was isolated from single
retinas of 6–10 mice per group. To qualitatively determine the
expression profile of the NOX1, NOX2, NOX4, and NOX5
isoforms in distinct retinal cell types, RNA was isolated from
cultured rat ganglion cells, glia, and microglia, and bovine
retinal endothelial cells and pericytes. The method for the
primary culture of rat ganglion cells, glia and bovine retinal
endothelial cells and pericytes is described previously (14, 58).
NOX isoform expression was qualitatively assessed in a hu-
man retinal cDNA preparation (BioChain, Newark, CA).
Confirmation of the absence of NOX1 mRNA in NOX1 KO
retinas, NOX2mRNA inNOX2KO retinas, andNOX4mRNA
in NOX4 KO retinas was achieved from amplifications using
primers located within the exonic regions disrupted in each
NOX KO mouse strain. The primer sequences used in the
study are found in Supplementary Table S2.
Reactive oxygen species
The DHEmethodwas used to measure ROS levels in single
retina. Eyes were enucleated and immediately frozen in OCT
compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan).
Unfixed cryosections (20lm) were incubated with sterile PBS
containing 0.1% d-glucose (Ajax Chemicals, Sydney, Aus-
tralia), l-arginine (50 lM; Sigma, St. Louis, MO), NADPH
(100 lM; Roche Applied Science, IN), and DHE (2 lM; Sigma)
for 30min at 37C, as previously described (11, 46). These
sections were then photographed using an inverted fluores-
cence microscope (Eclipse TE2000; Nikon Instrument, Inc.,
Melville, NY) equipped with a digital camera and interfaced
with a computer running NIS-Elements version 2.20 (Nikon
Instruments, Inc.) in the same exposure conditions; the in-
tensity of the staining was measured using the Image J
program (version 1.37; National Institutes of Health). Five
mice per group were evaluated. From each animal, three
sections were randomly selected and labeling intensity was
measured in the region of the retinal surface associated with
pre-retinal neovascularization (inner limiting membrane
and ganglion cell layer). Immunolabeling for nitrotyrosine
was performed as described above (53). Sections were in-
cubated with 0.5% skimmilk for 10min, which was followed
by incubation with an anti-nitrotyrosine antibody overnight
at 4C (1:400; Millipore, Temecula, CA). Five animals per
group were evaluated.
Primary cultures of rat retinal microglia
under hypoxic conditions
The methods for culturing primary rat retinal microglia
are as described previously (14). Characterization of cul-
tured retinal microglia was performed with immunohisto-
chemistry for Iba1 (14). Dishes containing purified retinal
microglia were placed in a Modular Incubator Chamber
(MIC101; QNA International Pty Ltd, Glenferrie South,
Victoria, Australia). The hypoxic conditions were estab-
lished by flushing the chamber for 4min with 0.5%O2, 94.5%
N2, and 5% CO2. The same gas mixture was then pumped
into the chamber and immediately the chamber was sealed.
Microglia were exposed to GKT137831 at concentrations of
0.1, 5, and 10 lM. The chamber was then placed in a 37C
incubator for 4 h. Comparisons were made to microglia
exposed to normoxic conditions.
ROS levels in rat retinal microglial lysates
Primary cultured rat retinal microglia were washed with
Hank’s balanced salt solution (HBSS) for 2min followed by a
30-min incubation with 5lM DHE at 37C in 5% CO2, in the
dark. After incubation, cells werewashedwithHBSS and then
imaged immediately using an Eclipse TE2000 inverted fluo-
rescence microscope (Nikon Instruments, Inc.) and image-
processing computer software (NIS-Elements version 2.20;
Nikon Instruments, Inc.). Fluorescence intensity of cells was
used as a measure of intracellular ROS levels using Image J
analytical software (version 1.44). For quantitation, a mini-
mum of 15 randomly selected cells from three different fields
from each dish was evaluated. The intensity of fluorescence in
a blank space between two cells wasmeasured as background
intensity. Three independent experiments were performed in
each group with a minimum of three replicates.
Statistics
All datawere analyzed using the GraphPad Prism software
(v.5; GraphPad Software, Inc., LA Jolla, CA). Both animal and
cell culture data sets were assessed for normality, and in the
case of more than two treatments, a one-way ANOVA
(parametric) was followed by a Bonferroni post hoc analysis or
Kruskal–Wallis or by Mann–Whitney U tests (nonpara-
metric). Either an unpaired t-test (parametric) or a Mann–
Whitney U test (nonparametric) was conducted when there
were only two treatments. Investigators were masked to the
groups. A value of p< 0.05 was considered significant.
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Iba1¼ ionizing binding adaptor molecule-1
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